Medical experts have renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) as of May 2026 [2].
The change aims to correct a fundamental misunderstanding of the disorder. By removing the primary focus on ovarian cysts, the new terminology encourages clinicians to treat the condition as a systemic metabolic issue rather than a localized reproductive problem.
Dr. Helena Teede, an endocrinology researcher, said the condition affects tens of millions of women worldwide [1]. She said the new name better reflects the systemic nature of the disorder [1]. "It feels fantastic to finally say the name we have been advocating for years," Teede said.
The Endocrine Society pushed for the change because the previous name was considered inaccurate. A spokesperson for the society said the old name reduced a complex hormonal disorder to a misunderstanding about cysts, which contributed to missed diagnoses and inadequate treatment [3].
The transition to PMOS is being communicated globally. In the U.S., health reports have highlighted the shift toward metabolic awareness [3]. In Pakistan, physician Dr. Nadeem Naeem discussed the implications of the change on the SAMAA TV morning show "Subh Ka Samaa" [4].
The shift emphasizes that the syndrome involves multiple endocrine glands and metabolic processes. This broader perspective is intended to ensure patients receive comprehensive care that addresses insulin resistance, and other hormonal imbalances—rather than focusing solely on the ovaries.
The announcement in May 2026 [2] marks the culmination of years of advocacy by researchers and medical societies to align the clinical name with the actual pathology of the disease [1].
“"The old name reduced a complex hormonal disorder to a misunderstanding about cysts."”
The transition from PCOS to PMOS represents a paradigm shift in women's healthcare. By centering the name on 'polyendocrine' and 'metabolic' functions, the medical community is pivoting away from a reproductive-centric diagnosis toward a systemic endocrine framework. This is likely to reduce diagnostic delays for patients who do not present with traditional ovarian cysts but suffer from the metabolic dysfunctions associated with the syndrome.
